Abstract
Abnormal cellular proliferation is associated with the pathology of several diseases, including cancer, atherosclerosis and restenosis post-angioplasty. Therefore, anti-proliferative therapies may be a suitable approach to treat these disorders. Candidate targets for such strategies include specific components of the cell cycle machinery. Progression through the cell cycle in mammalian cells requires the activation of several cyclin-dependent protein kinases (CDKs) through their association with regulatory subunits called cyclins. Active CDK/cyclin holoenzymes phosphorylate cellular proteins including the retinoblastoma susceptibility gene product (pRb) and the related pocket proteins p107 and p130. Several compounds have been described that directly or indirectly inhibit the activity of CDKs, which results in a suppression of cell growth. In this review, we will discuss the use of drugs targeting CDKs and their therapeutic application in animal models and clinical trials.
Keywords: Inhibition, Cellular proliferation, Drug targeting, Cyclin dependent kinases, Chemical inhibitors, Purines
Current Pharmaceutical Biotechnology
Title: Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Volume: 1 Issue: 1
Author(s): Ignacio Perez-Roger, Carmen Ivorra, Antonio Diez, Maria Jose Cortes, Enric Poch, Silvia M. Sanz-Gonzalez and Vicente Andres
Affiliation:
Keywords: Inhibition, Cellular proliferation, Drug targeting, Cyclin dependent kinases, Chemical inhibitors, Purines
Abstract: Abnormal cellular proliferation is associated with the pathology of several diseases, including cancer, atherosclerosis and restenosis post-angioplasty. Therefore, anti-proliferative therapies may be a suitable approach to treat these disorders. Candidate targets for such strategies include specific components of the cell cycle machinery. Progression through the cell cycle in mammalian cells requires the activation of several cyclin-dependent protein kinases (CDKs) through their association with regulatory subunits called cyclins. Active CDK/cyclin holoenzymes phosphorylate cellular proteins including the retinoblastoma susceptibility gene product (pRb) and the related pocket proteins p107 and p130. Several compounds have been described that directly or indirectly inhibit the activity of CDKs, which results in a suppression of cell growth. In this review, we will discuss the use of drugs targeting CDKs and their therapeutic application in animal models and clinical trials.
Export Options
About this article
Cite this article as:
Perez-Roger Ignacio, Ivorra Carmen, Diez Antonio, Cortes Jose Maria, Poch Enric, Sanz-Gonzalez M. Silvia and Andres Vicente, Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases, Current Pharmaceutical Biotechnology 2000; 1 (1) . https://dx.doi.org/10.2174/1389201010001010107
DOI https://dx.doi.org/10.2174/1389201010001010107 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Biologically Active Insulin-derived Peptides
Protein & Peptide Letters Hsp70 Structure, Function, Regulation and Influence on Yeast Prions
Protein & Peptide Letters The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies
Current Psychopharmacology Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry CXCR7 Participates in CXCL12-mediated Cell Cycle and Proliferation Regulation in Mouse Neural Progenitor Cells
Current Molecular Medicine Viral Disorder or Disordered Viruses: Do Viral Proteins Possess Unique Features?
Protein & Peptide Letters CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy Protein Kinase C Inhibitors in the Treatment of Diabetic Retinopathy. Review
Current Pharmaceutical Biotechnology Recent Advances in Two-Photon Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Application and Interpretation of Genome-Wide Association (GWA) Studies for Informing Pharmacogenomic Research - Examples from the Field of Age-Related Macular Degeneration
Current Molecular Medicine Naphthoflavones as Antiproliferative Agents: Design, Synthesis and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry The Role Oxidative Stress in the Pathogenesis of Eye Diseases: Currnt Status and a Dual Role of Physical Activity
Mini-Reviews in Medicinal Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents
Current Medicinal Chemistry - Anti-Cancer Agents